Occam Places David Mullarkey as CEO at Bluestar
Occam recently recruited David Mullarkey to Bluestar Genomics. He takes the helm of this rapidly evolving and highly innovative cancer detection company based on the scientific research of Stephen Quake of Stanford University. Dave comes to the role after having had great success as CEO of Omniome which was acquired by Pacific Biosciences and as President and COO of Ariosa Diagnostics sold to Roche. In addition to bringing deep content knowledge to Bluestar, he will provide strategic wisdom and operational discipline to the company’s imminent product launch and commercialization.
Occam Global is an international life science executive search and leadership advisory firm dedicated to building management teams for innovative companies in the biotech, techbio, life sciences, and venture capital sectors. Our firm’s unique strength lies in our seamless access to elite talent, proven expertise in aligning exceptional business and scientific leaders with optimal opportunities, and a steadfast dedication to creating meaningful industry impact, guided by elevated ethics and enlightened aggression. Trusted by entrepreneurs, investors, and corporations worldwide, Occam Global is recognized as the premier partner for executive search and recruitment in the life sciences. Our success is rooted in establishing trust, cultivating and valuing relationships, and committing to serve as forthright and good-humored partners in realizing extraordinary ambitions.